Creating Shared Value For Patients And Payers In Retinal Gene Therapies

Success in retinal gene therapy isn’t defined by clinical outcomes alone—it depends on delivering meaningful value to patients, providers, and payers. As these therapies advance, sponsors must navigate a landscape where demonstrating impact requires more than strong data; it requires a clear, credible value story.

This article outlines how developers can better align clinical outcomes with real patient needs and payer expectations. It highlights strategies for selecting outcomes that resonate with both clinicians and those making coverage decisions, building evidence packages that support reimbursement, and addressing access challenges unique to high‑cost, high‑impact ophthalmology therapies.

By integrating clinical, economic, and patient‑centered value early in development, sponsors can position retinal gene therapies for stronger adoption, broader access, and greater long‑term success.